// App-Quantinova.ai

POS1025 (2022) : COMPARISON OF COMPOSITE INDICES FOR DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: A POST-HOC ANALYSIS FROM SELECT-PsA 1

Researchers

Presenter

  • J. S. Smolen

Principal Investigators

  • E. Lubrano

  • M. Kishimoto

  • A. Balanescu

  • V. Strand

  • T. Gao

  • N. Vranich

  • R. Lippe

  • W. Tillett

Medical Centers

  • Medical University of Vienna, Vienna, Austria

  • Dept. of Medicine and Health Science, University of Molise, Campobasso, Italy

  • Department of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan

  • Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology, Cantacuzino Hospital, Bucharest, Romania

  • Stanford University, Department of Pathology, Palo Alto, United States of America

  • AbbVie Inc, Immunology, Illinois, United States of America

  • AbbVie Deutschland GmbH & Co. KG, Immunology, Berlin, Germany

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

Locations

  • Austria

  • Italy

  • Japan

  • Romania

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

  • Malondialdehyde

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved